Apocynin stimulates osteoblast differentiation and inhibits bone-resorbing mediators in MC3T3-E1 cells

Cellular Immunology

Volumn 270, Issue 2, 2011, Pages 224-229

  Lee, Young Soon ^a   Choi, Eun Mi ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Apocynin; Differentiation; Osteoblastic MC3T3 E1 cells

Indexed keywords

ALKALINE PHOSPHATASE; APOCYNIN; CALCIUM; COLLAGEN; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ELECTRON TRANSPORT; ENZYME ACTIVITY; MINERALIZATION; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL;

3T3 CELLS; ACETOPHENONES; ANIMALS; ANTIMYCIN A; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; ELECTRON TRANSPORT; INTERLEUKIN-6; MICE; OSTEOBLASTS; OSTEOPROTEGERIN; RANK LIGAND; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051670007     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.05.011     Document Type: Article

References (36)

1. Jezek P., Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int. J. Biochem. Cell Biol. 2005, 37:2478-2503.
2. Nishikawa T., Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid. Redox. Signal 2007, 9:343-353.
3. Han Y.H., Park W.H. Growth inhibition in antimycin A treated-lung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis. Lung Cancer 2009, 65:150-160.
4. Manolagas S.C. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 2000, 21:115-137.
5. R.L. Jilka, Cytokines, bone remodeling, and estrogen deficiency: A 1998 update, Bone 23 (1998) 75-81.
6. Spelsberg T.C., Subramaniam M., Riggs B.L., Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 1999, 13:819-828.
7. Issenman R.M. Bones in Crohn's: Cytokines, a missing link?. J. Pediatr. Gastroenterol. Nutr. 1997, 24:361-362.
8. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
9. Simons J.M., t'Hart B.A., Ip Vai Ching T.R.A.M., Van Dijk H., Labadie R.P. Metabolic activation of natural phenols into selective oxidative burst agonists by activated human neutrophils. Free Radic. Biol. Med. 1990, 8:251-258.
10. Muijsers R.B.R., van den Worm E., Folkerts C.J., Beukelman C.J., Koster A.S., Postma D.S., Nijkamp F.P. Apocynin inhibits peroxynitrite formation by murine macrophages. Br. J. Pharmacol. 2000, 130:932-936.
11. Dodd-O J.M., Pearse D.B. Effect of the NADPH oxidase inhibitor apocynin on ischemia - reperfusion lung injury. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H303-H312.
12. Muijsers R.B., van Ark I., Folkerts G., Koster A.S., van Oosterhout A.J., Postma D.S., Nijkamp F.P. Apocynin and 1400W prevents airway hyperresponsiveness during allergic reactions in mice. Br. J. Pharmacol. 2001, 134:434-440.
13. Zhang Y., Chan M.M.K., Andrews M.C., Mori T.A., Croft K.D., McKenzie K.U., Schyvens C.G., Whitworth J.A. Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. American Journal of Hypertension 2005, 18:910-916.
14. Barbieri S.S., Cavalca V., Eligini S., Brambilla M., Caiani A., Tremoli E., Colli S. Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms. Free Radical Biology and Medicine 2004, 37:156-165.
15. Kanno S., Anuradha C.D., Hirano S. Localization of zinc after in vitro mineralization in osteoblastic cells. Biol. Trace Elem. Res. 2001, 83:39-47.
16. Sezer O., Heider U., Zavrski I., Kuhne C.A., Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003, 101:2094-2098.
17. Bellows C.G., Aubin J.E., Heersche J.N.M. Initiation and progression of mineralization of bone nodules formed in vitro: the role of alkaline phosphatase and organic phosphate. Bone Miner. 1991, 14:27.
18. Yang Q., Populo S.M., Zhang J., Yang G., Kodama H. Effect of Angelica sinensis on the proliferation of human bone cells. Clin. Chim. Acta 2002, 324:89.
19. Armstrong J.S. The role of the mitochondrial permeability transition in cell death. Mitochondrion 2006, 6:225-234.
20. Barja G., aging Endogenous oxidative stress: relationship to longevity and caloric restriction. Ageing Res. Rev. 2002, 1:397-411.
21. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
22. Lee Z.H., Kim H.H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 2003, 305:211-214.
23. Yamashita T., Yao Z., Li F., Zhang Q., Badell I.R., Schwarz E.M., Takeshita S., Wagner E.F., Noda M., Matsuo K., Xing L., Boyce B.F. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 2007, 282:18245-18253.
24. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., McCabe S., Elliott R., Scully S., Van G., Kaufman S., Juan S.C., Sun Y., Tarpley J., Martin L., Christensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C.R., Lacey D.L., Boyle W.J. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 2000, 97:1566-1571.
25. Gori F., Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Khosla S., Riggs B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000, 141:4768-4776.
26. Viereck V., Grundker C., Blaschke S., Siggelkow H., Emons G., Hofbauer L.C. The phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. J. Cell. Biochem. 2002, 84:725-735.
27. Dang Z.C., van Bezooijen R.L., Karperien M., Papapoulos S.E., Löwik C.W. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J. Bone Miner. Res 2002, 17:394-405.
28. Thirunavukkarasu K., Miles R.R., Halladay D.L., Yang X., Galvin R.J., Chandrasekhar S., Martin T.J., Onyia J.E. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-β (TGF-β): mapping of the OPG promoter region that mediates TGF-β effects. J. Biol. Chem. 2001, 276:36241-36250.
29. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 2001, 98:13960-13965.
30. Weitzmann M.N., Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 2006, 116:1186-1194.
31. Gilbert L., He X., Farmer P., Rubin J., Drissi H., van Wijnen A.J., Lian J.B., Stein G.S., Nanes M.S. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2αA) is inhibited by tumor necrosis factor-alpha. J. Biol. Chem. 2002, 277:2695-2701.
32. Kaneki H., Guo R., Chen D., Yao Z., Schwarz E.M., Zhang Y.E., Boyce B.F., Xing L. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J. Biol. Chem. 2006, 281:4326-4333.
33. Lu X., Gilbert L., He X., Rubin J., Nanes M.S., (Osx Transcriptional regulation of the osterix Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NFκB pathways. J. Biol. Chem 2006, 281:6297-6306.
34. Ding J., Ghali O., Lencel P., Broux O., Chauveau C., Devedjian J.C., Hardouin P., Magne D. TNF-α and IL-1β inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci. 2009, 84:499-504.
35. Hughes F.J., Howells G.L. Interleukin-6 inhibits bone formation in vitro. Bone Miner. 1993, 21:21-28.
36. Fang M.A., Hahn T.J. Effects of interleukin-6 on cellular function in UMR-106-01 osteoblastlike cells. J. Bone Miner. Res. 1991, 6:133-139.